^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Peripheral T-cell Lymphoma |
| Regimen: | DHAX (cytarabine + dexamethasone injection + oxaliplatin) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Peripheral T-Cell Lymphomas...Preferred regimens...DHAX (dexamethasone, cytarabine, oxaliplatin)
Second-line therapy and subsequent therapy for PTCL-NOS; EATL; MEITL....DHA (dexamethasone and cytarabine) + carboplatin was added as an option and the regimen was clarified as "DHA (dexamethasone, cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin)."
